Rivaroxaban for the treatment of deep vein thrombosis and ...

- the treatment effect (HR) of rivaroxaban for major bleedings at the upper 95% CI
Figure 11: Tornado plot - Net Monetary Benefit of rivaroxaban vs. LMWH/VKA, 6 months
of treatment, lifetime horizon, duration specific inputs (reproduction of Figure 6, p. 34,
Clarification letter 17 December 2011)
Results for the PSA were run over 1,000 iterations, using effectiveness data specific to patients treated
for 6 months under a lifetime horizon are presented in Figure 12 for the cost-effectiveness plane and
Figure 13 for the CEAC.
OWSA Tornado diagram for strategy (Net monetary benefit, QALY based): 1 vs 2 (lifetime)
HR of VTE in 6 months patient group (EINSTEIN acute)
HR of major bleed in 6 months patient group (EINSTEIN acute)
Cost of ambulatory visits (OPs by different treatment setting plus
district nurse)
Cost of GP visit VKA
Number of warfarin monitoring visits during initiation period (months 1-
3)
Number of warfarin monitoring visits per period of 3 months, after
initiation period
Disutility associated with WARF
Discount rate applied to outcomes
Mean age cohort
State-related mortality (all parameters)
Proportion of patients who self inject LMWH
Probability major bleed is intra-cranial
Death given treated PE (overall)
Probability of major bleed in 6 months patient group over 0-3 months
(EINSTEIN acute)
Cost of subsequent appointments for follow-up VKA
-300 -200 -100 0 100 200 300 400 500 600 700
The manufacturer reported that rivaroxaban had a 85.0% chance of being cost-effective at a WTP of
£20,000 per QALY gained. Rivaroxaban was dominant (provided more QALYs at a lower cost) in
68.7% of cases and was dominated (provided less QALYs at a higher cost) in 6.4% of iterations.
125
Copyright 2012 Queen's Printer and Controller of HMSO. All rights reserved.
Low variation High variation